CIA
RCUS icon

Capital Impact Advisors’s Arcus Biosciences RCUS Stock Holding History

Capital Impact Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,280
Closed -$464K – 99
2023
Q4 		$464K Hold
24,280
– – 0.61% 78
2023
Q3 		$436K Buy
24,280
+2,411
+11% +$48.4K 0.73% 66
2023
Q2 		$444K Buy
21,869
+1,368
+7% +$26K 0.49% 103
2023
Q1 		$374K Buy
20,501
+4,344
+27% +$83K 0.46% 103
2022
Q4 		$334K Buy
16,157
+7,757
+92% +$213K 0.33% 131
2022
Q3 		$241K Buy
8,400
+331
+4% +$8.75K 0.24% 163
2022
Q2 		$204K Buy
+8,069
New +$198K 0.19% 197

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital Impact Advisors's RCUS Position: Q1 2024 in Review

Capital Impact Advisors sold out of Arcus Biosciences (RCUS) in Q1 2024, closing a stake of 24,280 shares — an estimated $464K sold.

Capital Impact Advisors first reported a position in RCUS in Q2 2022 and held it in 7 quarters. The position peaked at $464K in Q4 2023. 172 funds tracked by Wall St. Rank hold RCUS as of Q1 2024.

  • Capital Impact Advisors reported no remaining Arcus Biosciences position as of Q1 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 24,280 Arcus Biosciences shares in Q1 2024, an estimated $464K.
  • Capital Impact Advisors first reported a position in Arcus Biosciences in Q2 2022 and held it in 7 quarters.
  • Capital Impact Advisors's Arcus Biosciences position peaked at $464K in Q4 2023.
  • 172 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2024.

Based on Capital Impact Advisors's 13F filing for Q1 2024, filed 15 May 2024.